Presentation-Paediatric onset multiple sclerpsis

Evidence from observational studies Natalizumab A large real-world NATALIZUMAB study 101 patients with POMS 45 treatment naive, 67 switched from first line injectables, 7 from immunosuppressants Significant reduction of ARR from 2.3 to 0.1 during the follow op mean of 3 years Free of any clinical or MRI activity 58% No significant occurrences of AEs The pharmacokinetic/pharmacodynamic properties and the real-world efficacy/safety data are similar to those in adults AE: adverse event; ARR: annualized relapse rate; MRI: magnetic resonance imaging; POMS: pediatric onset multiple sclerosis Ghezzi A, et al. BMC Neurol. 2015 Sep 25;15:174. doi: 10.1186/s12883-015-0433-y; Alroughani R, et al. Pediatr Neurol. 2017 May;70:56-60.